Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 229-233

  Grosios, K ^a   Loadman, P M ^a   Swaine, D J ^a   Pettit, G R ^b   Bibby, M C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

5FU; Colon tumours; Combretastatin A 4 pro drug; Pharmacokinetics

Indexed keywords

COMBRETASTATIN A4; FLUOROURACIL; PRODRUG; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; COLON ADENOCARCINOMA; DRUG ACTIVITY; ENDOTHELIUM CELL; FEMALE; MOUSE; NECROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROURACIL; MICE; NECROSIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PRODRUGS; STILBENES; TUBULIN MODULATORS;

EID: 0034109559     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. McGown AT, and Fox BW: Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin-A4 and amphethinile. Anti Cancer Drug Design 3: 249-254, 1989).
2. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garciakendall D: Antineoplastic agents. 145. Isolation and structure of the strong cell-growth and tubulin inhibitor combretastatin-a-4. Experientia 45: 209-211, 1989.
3. Pettit GR, Temple C, Narayanan VL, Varma R, Simpson M.J, Boyd MR, Rener GA and Bansal N: Antineoplastic agents-322 - synthesis of combretastatin A-4 pro-drugs. Anti Cancer Drug Design 10: 299-309, 1995.
4. Pettit GR and Rhodes MR: Antineoplastic agents 389. New syntheses of the combretastatinA-4pro-drug. Anti Cancer Drug Design 13: 183-191, 1998.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4 an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997.
6. Grosios K, Holwell S, McGown AT, Pettit GR, Bibby MC: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate pro-drug. Br J Cancer in press.
7. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anti-cancer Res 19: 189-95, 1999.
8. Li L, Rohiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42: 899-903, 1998.
9. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T and Wallace J: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in experimental neoplasia (Second Edition). Br J Cancer 77: 1-10, 1998.
10. Hill SR, Pollard LA, Bibby MC. Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma. Anticancer Res 12: 2169-2176, 1992.
11. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ: Protocols for screening chemical agents and natural products against animal tumours and other biological systems (3rd edition). Cancer Chemother Rep 3: 1-103, 1972.
12. Loadman PM, Bibby MC, Double JA, McElhinney RS: Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. Investigational New Drugs 10: 149-158, 1992.
13. Bibby MC, Loadman PM, Al-Ghabban AF, Double JA: Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. Br J Cancer 65: 347-350, 1992.
14. Bibby MC, Sleigh NR, Loadman PM, Double JA: Potentiation of EO9 anti-tumour activity by hydralazine. Eur J Cancer 29A: 1033-1035, 1993.
15. Cowen SE, Loadman PM, Double JA, Bibby MC: Hydralazine alters murine mitomycin C plasma pharmacokinetics: a possible explanation of drug potentiation. Br JCancer 69: 41, 1994.